ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 1

Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

, , ,

Experts discuss the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plus ipilimumab for first-line treatment of advanced renal cell carcinoma (RCC), and how these mature overall survival (OS) data influence the view of nivolumab plus ipilimumab as a frontline option, alongside insights from efficacy, safety, post hoc subgroup analyses (Albiges et al, Eur Urol, 2022), and health-related quality of life (HRQOL) data (Cella et al, J Clin Oncol, 2022).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data
    EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes
    EP. 3: Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC
    EP. 4: RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection
    EP. 5: Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment
    EP. 6: Navigating RCC Progression: Optimizing Treatment Sequence After the First Line
    EP. 7: Post-Immunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
    EP. 8: Emerging Therapies in RCC: Shaping Future Treatment Sequences
    EP. 9: RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

    Video content above is prompted by the following:

    • Please walk us though the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plusipilimumab for first-line treatment of advanced RCC.
    • How do these mature OS data influence your view of nivolumab plusipilimumab as a frontline option?
    • Please share your insights from efficacy and safety data, post hoc subgroup analyses, or HRQOL data. How you interpret these data?
    x